Tuesday 19 September 2017 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Premaitha - new Thermo Fisher loan: sends strong message to Illumina: BUY

By HotStockRockets | Sunday 16 July 2017


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Premaitha Health (NIPT) has announced that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific  announced on 14 December 2015 and extended as announced on 23 September 2016. This is good news.

Thermo is a true giant and is standing behind Premaitha in its patent battle with US corporate fascists Illumina. Thermo Fisher will make available to Premaitha an additional secured loan facility of $5 million of which 80% is drawn down at once "for the purposes of working capital to support commercial growth strategies" The rest is subject to milestones. Interest is at 6%, the loan is not repayable until 2023 and Thermo will also get 28,938,797 warrants with a strike price of 10.725p.

This is better than dilution and means Premaitha can crack on with expansion and getting towards breakeven ASAP and also fight Illumina hard in the courts. The US bully boys thought Premaitha was a small firm, a pushover. It reckoned without Thermo's support.

As noted before we expect Illumina to either settle or be defeated and that is far from discounted in a share price of 9.25p-9.75p. BUY

This article first appeared on HotStockRockets - to catch the next red hot share tip from the HotStockRockets team out shortly for just £5 click HERE


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on NIPT


Comments

Comments are turned off for this article.




Site by Everywhen